Patients with a very rare immune disorder who have gotten the gene therapy have experienced sustained long-term immune ...
Enhertu Benefit in HER2-Low Breast Cancer That's Also HR-Negative Supported by Longer Follow-Up Data
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.
The funding includes an initial tranche of $7.5 million in equity and technical support, and the biotech and the foundation will form a joint steering committee.
In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...
NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.
The firm amended the terms of a deal with Pfizer and submitted results from the BREAKWATER trial of Braftovi, Erbitux, and chemo against chemo alone.
Two recent studies identified gene knockouts that may make CAR T-cell therapy more effective, but the next step is applying ...
The cell and gene therapy manufacturing company will provide services to advance early-stage translational R&D at Mass General Brigham.
The trial, performed at Radboud University Medical Center, will test TGW211, which involves a trigger designed to limit off-target effects of the radioactive material.
The company is studying the mRNA tumor-associated antigen vaccine as a monotherapy and in combination with Keytruda.
There was strong uptake of Rybrevant-Lazcluze in first-line advanced, EGFR-mutated NSCLC after the combo bested AstraZeneca's Tagrisso in the MARIPOSA trial.
The firm originally filed a BLA in 2023, but the FDA twice delayed its approval decision on the gene therapy and requested more CMC information.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback